

AGREEMENT WITH PATIENT ASSOCIATION

Project support

This Agreement is made by and between

JANSSEN-CILAG A/S, a company with its registered address at Bregnerødvej 133 2, DK-3460 Birkerød , Denmark, [VAT no.: DK19248615] hereinafter "**J&J AFFILIATE**";

and

LYLE LYMFEBKRÆFT OG LEUKÆMI, Banetoften 26, 4700 Næstved, Denmark, [Org. ID no 31 30 68 33 , hereafter referred to as "**Organization**"

J&J AFFILIATE and Organization are individually referred to as a "**Party**", collectively referred to as the "**Parties**".

WHEREAS:

- J&J AFFILIATE is a research-oriented pharmaceutical company active in the development and marketing of medicinal products
- Organization is a patient advocacy Group for Lymphoma, Leukemia and MDS
- Organization has asked J&J AFFILIATE to support one of its projects and J&J AFFILIATE has agreed to provide support under the terms of this agreement.

THE PARTIES TO THIS AGREEMENT AGREE AS FOLLOWS:

Article 1: Scope

1. Organization will carry out the Project for which J&J AFFILIATE will provide support and Organization shall ensure that the contribution is used in a professional and ethical manner consistent with this Agreement and applicable rules, legislation and code of practice. More details on the Project (including the objective, roles and responsibilities of both parties, contact persons, outputs, reporting and timelines) are included in **Annex 1**,
2. Organization will use the support provided by J&J AFFILIATE exclusively for the purpose of the Project.

Article 2: Support

1. The total amount of support that J&J AFFILIATE will provide for the Project amounts to 131,000.00 DKK.
2. Further details on the level and type of support, including payment method and timelines, are included in **Annex 1**.
3. Organization and J&J AFFILIATE acknowledge and agree that the support shall not obligate Organization to purchase, use, recommend, or arrange for the use of any products of J&J AFFILIATE.
4. EU and National legislation and codes of practice prohibiting the advertising of prescription-only medicines to the general public, apply. Organization and J&J AFFILIATE acknowledge and agree that J&J AFFILIATE shall not request, nor shall Organization undertake, the promotion of a particular prescription-only medicine.
5. Organization represents and warrants that it is a tax-exempt entity under the applicable laws and that it is authorized to accept support in the form of financial contribution or other support from private companies such as J&J AFFILIATE, and that, to the extent applicable, it has performed the necessary notifications or received the necessary approvals. Organization will also keep J&J AFFILIATE regularly informed of its direct or indirect relationships with government officials and/or government authorities.
6. If any funds provided by J&J AFFILIATE to Organization under this Agreement remain upon completion of the Project, such surplus shall be refunded by Organization to J&J AFFILIATE within forty-five (45) days of completion of the project.

Article 3: Use of name and logo or other proprietary materials

1. Organization will publicly recognize that J&J AFFILIATE provides support for the Project

Article 4: Transparency

1. In order to create appropriate transparency on the support to patient organizations by J&J AFFILIATE, and in line with the applicable code(s) of practice, J&J AFFILIATE will make the existence of this agreement and details relating thereto publicly available at Janssen Denmark Website www.janssen.com/denmark and Organization explicitly agrees with such disclosure. More precisely, J&J AFFILIATE will make the following details publicly available:

- a) Date that the contract was executed;
- b) Name of the patient organization;
- c) Country of the patient organization;
- d) Web address of the patient organization, if available;
- e) Description of the nature and the purpose of the contribution;
- f) Amount as contracted, if financial.

In addition, J&J AFFILIATE will also make copies of this contract available to interested parties upon their request.

2. J&J AFFILIATE is entitled to increase the level of details made publicly available to patient organizations either as required by applicable rules and legislation, or upon notice to Organization.
3. This article shall survive any termination of the Agreement.

Article 5: Term and termination

1. This Agreement will take effect on the date when the last of the parties has signed, hereafter the Effective Date, and will remain in effect up until the completion of the Project as described in **Annex 1.**]
2. Both parties have the right to terminate this Agreement upon 2 months written notice notified by registered mail. The respective rights and obligations of both parties in case of early termination of the Project or this Agreement are included in **Annex 1.**

Article 6: General Provisions

1. General Anti-Corruption Compliance Provision

Neither party shall perform any actions that are prohibited by local and other anti-corruption laws (collectively "**Anti-Corruption Laws**") that may be applicable to one or both parties to the Agreement. Without limiting the foregoing, neither party shall make any payments, or offer or transfer anything of value, to any government official or government employee, to any political party official or candidate for political office or to any other third party related to the transaction in a manner that would violate Anti-Corruption Laws.

2. Personal Data

J&J AFFILIATE needs to collect personal information from the Organization, and J&J AFFILIATE and its affiliates will use such information, in order to manage J&J AFFILIATE's relationship with the Organization pursuant to this letter agreement. A list

of affiliates is at <http://www.investor.jnj.com/sec.cfm> (click on the link to Form 10K, Exhibit 21, under "SEC Filings"). J&J AFFILIATE may also disclose the Organization's personal information to third-parties service providers, such as technology and marketing service providers, and parties engaged in the organization of events, including hotels and airlines. If the Organization does not provide the personal information requested, J&J AFFILIATE will not be able to fulfill its obligations to the Organization pursuant to this letter agreement. Based on the J&J AFFILIATE's legitimate interests, J&J AFFILIATE may use the Organization's personal information to compile statistical data based on the information in our databases, as well as on surveys, customer feedback questionnaires, and similar communications.

The Organization may contact J&J AFFILIATE with questions or request to review the personal information J&J AFFILIATE has collected and/or to request its correction, deletion, blocking, data portability or restriction at: jacdk@its.jnj.com The Organization may also lodge a complaint with a data protection authority for the Organization's country or region.

The use and disclosure of personal information may involve a transfer to other jurisdictions, including the U.S., which may provide for different data protection rules than in the Organization's country. Appropriate contractual and other measures are in place to protect personal information when it is transferred. The Organization may obtain a copy of these measures by contacting the J&J AFFILIATE's data protection officer responsible for the Organization's country or region, if applicable, at emeaprivacy@its.jnj.com.

J&J AFFILIATE will retain the Organization's personal information for as long as needed or permitted in the light of the purpose(s) for which it was obtained, based on: (i) the length of time J&J AFFILIATE has an ongoing relationship with the Organization; (ii) whether there is a legal obligation to which J&J AFFILIATE is subject; and (iii) whether retention is advisable in light of the J&J AFFILIATE's legal position.

3. Pandemic

If either of the Parties is unable to perform its obligations under this Agreement due to its evolving policies related to the COVID-19 health pandemic, or because of uncertainty related to the impact of COVID-19, either Party may terminate this Agreement upon not less than 10 days' written notice to the other, in which case neither Party shall have any further obligations to the other, including any obligation to pay for goods and/or services not actually performed and/or delivered prior to the written notice of termination.

J&J AFFILIATE may cancel any meeting upon notice without liability, cancellation fees or damages, in the event of the COVID-19 health pandemic and/or any other health pandemic for which the World Health Organization and/or other local governmental and/or health authorities issue travel alerts or warnings recommending against non-essential travel to Event's location and/or against meetings of groups of people, making

it inadvisable, illegal, or impossible to provide the facilities or to have the meeting/Event, or if the meeting/Event could create a significant risk to the health and safety of participants.

In case of early termination or cancellation by J&J Affiliate due to the abovementioned reasons, the Recipient will be reimbursed for any actual and documented costs, which are directly related to the Project and have been already incurred and which cannot be recouped through cancellation policies. If the meeting/Event is a physical meeting and is converted into digital form or otherwise converted into a different form than originally agreed upon, the meeting/Event costs and related payment will be re-evaluated by the Parties. In particular, the organizer or the delegated agency shall provide J&J AFFILIATE with a list and detailed breakdown of the actual costs incurred for the provision of the obligations set out in this Agreement to allow performance in the changed form (which are expected to be lower than the costs that may have been incurred for a face-to-face meeting/Event). In case of such conversion to a different meeting/Event form, J&J AFFILIATE shall be obliged to pay only the newly identified amount or shall be entitled to receive reimbursement of the difference between the originally agreed upon contractual amount and the re-evaluated amount within 30 (thirty) days of J&J AFFILIATE's written request to the organizer. Such provisions shall take precedence over any other contracting provisions and/or other agreements and/or understandings that may have been reached between the Parties.

4. Governing Law

This Agreement shall be governed by and construed under the laws of Denmark, without reference to the conflict of law rules.

5. Dispute Resolution

In case of any dispute arising out of or in connection with this Agreement, the Parties shall first attempt (in good faith) to reach an amicable settlement. Should such amicable settlement fail, the courts of Denmark shall have exclusive jurisdiction.

6. Electronic Signatures

The Parties explicitly agree to execute this Agreement by way of an electronic signature, and agree this shall constitute a valid and enforceable agreement between the Parties. The present Agreement is made in an electronic pdf-version (using Adobe Sign) which shall be electronically signed by each Party. Each Party hereby acknowledges receipt of the e-signed agreement, electronically signed for approval by both Parties.

For J&J AFFILIATE:

Mikkel Johansen

Elektronisk underskrevet af: Mikkel Johansen
Årsag: I acknowledge that my electronic signature
is the legally binding equivalent for my handwritten
signature
Dato: 29. sep. 2023 11:24 GMT+2

Head of Market Access & Policy

For ORGANIZATION:

Rita Christensen

Elektronisk underskrevet af: Rita Christensen
Årsag: I acknowledge that my electronic signature
is the legally binding equivalent for my handwritten
signature
Dato: 29. sep. 2023 12:17 GMT+2

Chairwoman

Annex 1: Project details

[

Article 1: More details on the Project (including the objective, roles and responsibilities of both parties, contact persons, outputs, reporting and timelines) are included in Annex 1.

Article 2: Further details on the level and type of support, including payment method and timelines, are included in Annex 1.

Payment method:

J&J AFFILIATE shall pay the Support within 45 days of being issued an invoice. Payments shall be made by bank transfer and only to a bank account held in the name of the Party on Invoice. Invoices should, as a minimum requirement, contain the following items: (a) full name and address of Party issuing the invoice; (b) where applicable tax number of Party issuing the invoice; (c) full name and address of the J&J AFFILIATE or its appointed agent; (d) place and date of invoice; (e) brief description of services invoiced with date of service rendered; and (f) where value added tax (VAT) is applicable, invoicing Party's VAT number, statement of net amounts invoiced, VAT rate, amount and gross amounts. J&J AFFILIATE will inform the Organization in case the invoice needs to be addressed to its appointed agent instead of to J&J AFFILIATE.

Reporting:

Within 1 month from the activity, the organization will write a small report as proof of event. The report should consist of:

- A letter on the organization's own letterhead-paper, signed by them, where they explain how the grant/support was used and confirm that the grant/support (amount) has been used as agreed upon

And at least one of following:

- Final agenda/Advertisement/ Receipts of costs/ detailed financial accounting for use of the support

Those parts can be combined in the same document, but the content must align with the requirements.



Patientforeningen for
Lymfekræft, Leukæmi og MDS



Ansøgning om sponsorat til patient-survey

Næstved, 28. juli 2023

LyLe, søger økonomisk støtte til at udføre en patient-survey.

Surveyen skal give indsigt i oplevelsen af medicin frie perioder blandt patienter, som typisk vil opleve disse perioder som en naturlig del af deres behandlingsforløb. Surveyen fokuserer således på patienter med hhv. kronisk lymfatisk leukæmi (CLL), Mantle celle lymfom (MCL), follikulært lymfom og Waldenstrøms sygdom.

Som medsponsor af surveyen vil du blive inviteret til online præsentation af survey-resultaterne og efterfølgende få tilsendt den endelige rapport i pdf.

Baggrund

Medicinfrie perioder er et kendt fænomen inden for behandling af leukæmi, men endnu ikke indenfor lymfekræft. Patienter vil typisk opleve en sådan periode af forskellige grunde. Fx at de responderer godt på behandlingen, at de oplever bivirkninger af en behandling, eller at de får en behandling, hvor medicinfriheden er en del af forløbet.

Hvad betyder denne – umiddelbart positive mulighed – for patienterne? Opleves den medicinfrie periode som en frihed og et løft af livskvaliteten? Eller skaber den uro og utryghed hos patienterne, fordi kontakten med sundhedsvæsenet mindskes, og frygten for tilbagefald (måske) forstærkes? Eller er der en kombination af følelser og oplevelser i kroppen af både utryghed og senere glæde ved friheden?

Det ved vi ikke i LyLe, og det er ikke undersøgt internationalt helt konkret for de angivne patientgrupper, der har erfaring med medicinfrie perioder. Derfor ønsker LyLe at få klarhed over emnet gennem en kvantitativ patient-survey, vi selv udvikler i samråd med en hæmatolog. Denne vil også vil kunne bistå i at få patienter med den rette erfaring til at gennemføre surveyen.

Formål

Via et kvantitativt spørgeskema blandt patienter med de angivne sygdomme ønsker LyLe at afdække erfaringer og holdninger inden for følgende temaer:

- Hvordan opleves de medicinfrie perioder – fysisk, psykisk og identitetsmæssigt?
- Giver perioderne anledning til følelsen af frihed og fornyet livskvalitet – eller skaber de uro og utryghed?
- Hvordan føler patienterne sig bedst støttet og fulgt op i de perioder, hvor de ikke er i medicinsk behandling?

Spørgeskemaet består af op til 12 spørgsmål plus demografiske data (køn, alder, region, sygdom dvs. CLL og indeholder kun lukkede spørgsmål, altså ingen åbne svarmuligheder.

LyLe – Patientforeningen for Lymfekræft, Leukæmi og MDS
Banetoften 26 · 4700 Næstved · tlf. 31 68 26 00 · CVR 31 30 68 33 · lyle@lyle.dk · www.lyle.dk



Patientforeningen for
Lymfekræft, Leukæmi og MDS



I Lyle vil vi bruge de indsamlede indsigter i det daglige arbejde for at sikre, at foreningen i fremtiden er rustet til at rådgive og støtte den voksende andel af patienter, der er i medicinfrige perioder, men måske stadig går til kontrol – og altså ikke har sluppet deres hæmatolog.

Surveyens set-up

End-mål for den kvantitative survey identificeres i samråd med hæmatolog ud fra, hvor mange patienter der har erfaring med medicinfrige perioder. Vi ved, at antallet af patienter for de angivne sygdomme er begrænset, og kun nogle af patienterne har erfaring med medicinfrige perioder. Rekruttering foregår derfor på flere platforme for hurtigst muligt at sikre en så repræsentativ svarprocent som mulig. Vi forventer, at rekrutteringen tager omkring 1 måned via følgende kanaler:

1. LyLes medlemmer via nyhedsbrev (eNyt) og så vidt muligt på de lukkede Facebook-grupper inden for de angivne sygdomme
2. Måltrettede dark posts på Facebook via LyLes åbne Facebook profil
3. Involvering af hæmatolog(er) til udbredelse af spørgeskema hos relevante patienter
4. Google Ads
5. Evt. bannerannoncering via Netdoktor.

Kommunikationsbureauet Molecule Consultancy vil stå for projektledelsen og den praktiske planlægning af surveyen, herunder udarbejdelse af procesplan, målgruppeidentifikation, udarbejdelse af spørgeskema, udsendelse og endelig databearbejdning, analyse og afrapportering. Lyle og Molecule involverer en af landets førende hæmatologer inden for blodkræftsygdomme i et samarbejde om validering af spørgeskemaet og formidling af surveyen blandt egne patienter. Lyle sender også link til surveyen til andre relevante hæmatologer med opfordring til at dele blandt deres patienter.

Molecule Consultancy A/S vil på vegne af Lyle indsamle og behandle data i henhold til Persondataforordningens retningslinjer. Data vil være i anonymiseret form og vil af Molecule Consultancy blive gemt 5 år efter afsluttet projekt. Surveyen vil ikke indeholde spørgsmål om specifikke lægemidler.

Timing

Vi starter udvikling af indsigtsanalysen, så snart vi har indhentet det fulde sponsorat. Vi håber, vi kan igangsætte udvikling i Q3 og starte rekruttering og indsamle data og afrapportere i Q4, 2023.



Patientforeningen for
Lymfekræft, Leukæmi og MDS



Budget

Nedenfor er skitseret budget for den samlede survey med udvikling, rekruttering og udarbejdelse af afrapportering. Alle priser er ex moms.

Projekt Budget EX moms

Opstart, workshop og projektbeskrivelse Debrief, research, id af scope og ansøgning Afholdelse af online miniworkshop med LyLe og Finn Stahlschmidt (LyLes journalist som selvstændig underleverandør) for afstemning af formål, vinkler og kanaler for rekruttering Udarbejdelse af projektbeskrivelse og tidsplan Løbende afstemning med LyLe og Finn Stahlschmidt.	50.000
Udvikling af survey Telefoninterview med hæmatolog for involvering i rekruttering og input til svarmuligheder i spørgeskema, inkl. koordinering, forberedelse og sammenfatning Udarbejdelse af spørgeskema til patienter med split på køn, sygdom og region, op til 12 spørgsmål + demografi, ingen åbne svar Afstemning af spørgeskema med hæmatolog, Finn Stahlschmidt og LyLe og endelig godkendelse Opsætning af spørgeskema i SurveyXact, inkl. testkørsel og indkøb af opsætningslicens og generering af link.	85.000
Rekruttering via LyLes nyhedsbrev (eNyt) og hæmatologer Opsætning af visuel indtrækker i LyLes nyhedsbrev med link til survey Koordinering med involveret hæmatolog for rekruttering af dennes patienter Henvendelse til øvrige relevante hæmatologer med opfordring til at dele link til survey.	15.000
Rekruttering via Facebook Ministrategi for 2 FB posts i hver to versioner, inkl. målgruppesegmentering, målsætning og timing Udvikling af 4x post copy Udvikling af 4x visuals Opsætning af Facebook posts og løbende optimering	




Patientforeningen for
Lymfekræft, Leukæmi og MDS



Annoncebudget sat til 20.000 dkk i alt for rekruttering Løbende afstemning med LyLe Annoncerne forventes at køre i 1 måned.	60.000
Rekruttering via Google Ads Produktion, opsætning og løbende optimering af 10 Google Search Ads inkl. minisøgeordsanalyse, estimering af KPI'er for kampagne, performance dashboard og oprettelse af Google Ads account for LyLe. Annoncebudget sat til 1 måneds kørsel.	55.000
Rekruttering via Netdoktor bannerannoncering Bannerannoncering på Netdoktor.dk under det sygdomsområde, der har største trafik (3 ads på siden) Budget sat til 200.000 visninger i alt (ikke klik) Udvikling af 3 GIF-animerede bannerannoncer Afstemning om rekruttering og løbende opfølgning på status med LyLe.	61.000
Analyse og afrapportering Indhentning og behandling af data Dataanalyse Opsætning af samlet data i Excel med split på køn, sygdom og region Udarbejdelse af rapport med opsummering af rekruttering og præsentation af resultater Præsentation af den fulde survey-rapport for LyLe og evt. sponsorer ved online møde, inkl. forberedelse og efterfølgende fremsendelse af endelig rapport i pdf til LyLe og sponsorer	67.000
Budget i alt ex moms i DKK	393.000

Finansiering og fakturering

LyLe ønsker projektet samfinansieret i form af supplerede sponsorater. Fx kan finansieringen deles i tre og bekoste hver sponsor DKK 131.000 (ex moms).



→ Læs også næste side

LyLe – Patientforeningen for Lymfekræft, Leukæmi og MDS
Banetoften 26 · 4700 Næstved · tlf. 31 68 26 00 · CVR 31 30 68 33 · lyle@lyle.dk · www.lyle.dk



Patientforeningen for
Lymfekræft, Leukæmi og MDS



Bemærk, at LyLe ikke er momsfrataget, som forening. Derfor fakturerer Molecule Consultancy sponsorerne direkte ex moms og håndterer betaling af øvrige underleverandører som Facebook og Finn Stahlschmidt.

Vi søger flere firmaer om støtte (3-4 stk.) og håber at få alle midler ind for at få foretaget denne undersøgelse.

Hvis evt. spørgsmål, så er I velkommen til at kontakte nedenstående.

Mange hilsner fra

Rita O. Christensen
Forkvinde

LyLe – Patientforeningen for Lymfekræft, Leukæmi og MDS
Banetoften 26 · 4700 Næstved · tlf. 31 68 26 00 · CVR 31 30 68 33 · lyle@lyle.dk · www.lyle.dk










[1970368] Sponsorship - Other

Endelig revisionsrapport

2023-09-29

Oprettet:	2023-09-29
Af:	J&J ICD system (icdsup@its.jnj.com)
Status:	Underskrevet
Transaktions-id:	CBJCHBCAABAAHFeA9-qNYIbYrRp6N3_sGhXWNaQ0PTeg

Oversigt over "[1970368] Sponsorship - Other"

-  Dokument oprettet af J&J ICD system (icdsup@its.jnj.com)
2023-09-29 - 08:58:37 GMT
-  Dokumentet blev sendt til Mikkel Johansen (mjohan12@its.jnj.com) til underskrivelse
2023-09-29 - 08:59:29 GMT
-  Dokumentet blev sendt til Rita Christensen (rita@lyle.dk) til underskrivelse
2023-09-29 - 08:59:29 GMT
-  E-mail blev vist af Mikkel Johansen (mjohan12@its.jnj.com)
2023-09-29 - 09:22:14 GMT
-  Mikkel Johansen (mjohan12@its.jnj.com) godkendte med Adobe Acrobat Sign.
Udfordring: Brugeren åbnede aftalen.
2023-09-29 - 09:23:27 GMT
-  Mikkel Johansen (mjohan12@its.jnj.com) godkendte med Adobe Acrobat Sign.
Udfordring: Brugeren fuldførte underskrivelsesprocessen ved at klikke på knappen "Klik for at underskrive".
2023-09-29 - 09:24:17 GMT
-  Mikkel Johansen (mjohan12@its.jnj.com) har accepteret vilkårene for anvendelse, og at forretninger skal foretages elektronisk ved hjælp af JOHNSON AND JOHNSON SERVICES, INC.
2023-09-29 - 09:24:41 GMT
-  Dokumentet blev e-underskrevet af Mikkel Johansen (mjohan12@its.jnj.com)
Årsag til underskrivelse: I acknowledge that my electronic signature is the legally binding equivalent for my handwritten signature
Dato for signatur: 2023-09-29 - 09:24:41 GMT - tidskilde: server
-  Mikkel Johansen (mjohan12@its.jnj.com) godkendte med Adobe Acrobat Sign.
Udfordring: Brugeren fuldførte underskrivelsesprocessen ved at klikke på knappen "Klik for at underskrive".
2023-09-29 - 09:24:41 GMT

 E-mail blev vist af Rita Christensen (rita@lyle.dk)

2023-09-29 - 10:15:58 GMT

 Rita Christensen (rita@lyle.dk) skrev en gyldig adgangskode, der er tildelt af afsenderen.

2023-09-29 - 10:16:14 GMT

 Rita Christensen (rita@lyle.dk) har accepteret vilkårene for anvendelse, og at forretninger skal foretages elektronisk ved hjælp af JOHNSON AND JOHNSON SERVICES, INC.

2023-09-29 - 10:17:58 GMT

 Dokumentet blev e-underskrevet af Rita Christensen (rita@lyle.dk)

Årsag til underskrivelse: I acknowledge that my electronic signature is the legally binding equivalent for my handwritten signature

Dato for signatur: 2023-09-29 - 10:17:58 GMT - tidskilde: server

 Aftale fuldført.

2023-09-29 - 10:17:58 GMT